Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding

American Journal of Hematology

Volumn 91, Issue 6, 2016, Pages E313-E314

  Epperla, Narendranath ^a   Kapke, Jonathan T ^a   Karafin, Matthew ^a   Friedman, Kenneth D ^a   Foy, Patrick ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BEVACIZUMAB; HEMOGLOBIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; ANEMIA; ARTICLE; BLEEDING; DISEASE ASSOCIATION; DISEASE SEVERITY; EPISTAXIS; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LENGTH OF STAY; MALE; PRIORITY JOURNAL; PROTEINURIA; RENDU OSLER WEBER DISEASE; SYSTEMIC THERAPY; TREATMENT RESPONSE; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BEVACIZUMAB; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 84966440683     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24367     Document Type: Article

References (6)

1. Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: Issues in clinical management and review of pathogenic mechanisms. Thorax 1999;54:714-729.
2. Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor- beta1 as well as high ALK1 tissue expression. Haematologica 2005;90:818-828.
3. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009;360:2143-2144.
4. Epperla N, Hocking W. Blessing for the bleeder: Bevacizumab in hereditary hemorrhagic telangiectasia. Clin Med Res 2015;13:32-35.
5. Sehl ME, M Gruber T, McWilliams JP, Marder VJ. Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia. Am J Hematol 2015;90:561-563.
6. Dupuis-Girod S, Giron I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. Jama 2012;307:948-955.